EUVIMEDEUVIMED entdecken
Crossref

TNM Staging and Overall Survival in Patients With Pheochromocytoma and Sympathetic Paraganglioma

Camilo Jimenez iD, Junsheng Ma, Alejandro Roman Gonzalez iD, Jeena Varghese, Miao Zhang, Nancy Perrier, Mouhammed Amir Habra, Paul Graham, Steven G Waguespack iD

The Journal of Clinical Endocrinology & Metabolism · 13.04.2023 · 108 (5) · 1132-1142

DOI: 10.1210/clinem/dgac677 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 26.11.2022. Verfasst von Camilo Jimenez und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Hauptthemen laut MEDLINE: Pheochromocytoma, Paraganglioma, Brain Neoplasms, Adrenal Gland Neoplasms. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 37 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Pheochromocytomas and paragangliomas (PPGL) are rare neuroendocrine tumors. Metastases develop in 15% to 20%. The American Joint Committee on Cancer (AJCC) established inaugural guidelines for PPGL tumor-node-metastasis (TNM) staging.

Objective

The objective of this analysis is to investigate the associations between TNM staging and overall survival (OS).

Methods

We retrospectively applied the TNM staging at the time of diagnosis of the primary tumor. The primary outcome was OS. Unadjusted survival rates were estimated by the Kaplan–Meier method. Cox proportional hazards regression models were used to evaluate the associations between OS and covariates of interest.

Results

The study included 458 patients. Median OS was 18.0 (95% CI, 15.6-not reached) years. At diagnosis, 126 (27.5%) tumors were stage I, 213 (46.5%) were stage II, 47 (10.3%) were stage III, and 72 (15.7%) were stage IV. The 10-year OS probabilities were 0.844 (95% CI, 0.768-0.928) for patients with stage I tumors, 0.792 (95% CI, 0.726-0.865) for stage II, 0.595 (95% CI, 0.435-0.813) for stage III, and 0.221 (95% CI, 0.127-0.384) for stage IV. Compared with stage I, the hazard ratios (HR) for death were 1.50 (0.87-2.57) for stage II, 2.85 (1.45-5.63) for stage III, and 8.88 (5.16-15.29) for stage IV (P < 0.001). Compared with patients with no germline mutations, those with RET 634/918 had better OS (HR: 0.28; 95% CI, 0.12-0.69). Other germline mutations, including SDHB, did not exhibit worse OS than patients with metastasis and sporadic disease.

Conclusion

OS rates correlated with the recently developed AJCC TNM staging and were not worse in hereditary disease. Stage IV disease exhibited a significantly shorter OS compared with stages I-III. Future staging systems could be adjusted to better separate stages I and II.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PheochromocytomaParagangliomaBrain NeoplasmsAdrenal Gland NeoplasmsHumansNeoplasm StagingRetrospective StudiesPrognosis

Stichwörter der Autor:innen

RETSDHBAJCC 8th edition cancer staging manualparagangliomapheochromocytomaprognosis

Autor:innen und Institutionen

  • Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Department of Endocrinology, San Vicente Fundación-Universidad de Antioquia, Medellin, Colombia.
  • Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

ORCID-Profile: Camilo Jimenez, Alejandro Roman Gonzalez, Steven G Waguespack

Zitieren

APA

Jimenez, C., Ma, J., Roman Gonzalez, A., Varghese, J., Zhang, M., Perrier, N., Habra, M. A., Graham, P., & Waguespack, S. G. (2023). TNM Staging and Overall Survival in Patients With Pheochromocytoma and Sympathetic Paraganglioma. The Journal of Clinical Endocrinology & Metabolism, 108(5), 1132-1142. https://doi.org/10.1210/clinem/dgac677

Vancouver

Jimenez C, Ma J, Roman Gonzalez A, Varghese J, Zhang M, Perrier N, et al. TNM Staging and Overall Survival in Patients With Pheochromocytoma and Sympathetic Paraganglioma. The Journal of Clinical Endocrinology & Metabolism. 2023;108(5):1132-1142. doi:10.1210/clinem/dgac677

BibTeX
@article{Jimenez2023,
  author = {Jimenez, Camilo and Ma, Junsheng and Roman Gonzalez, Alejandro and Varghese, Jeena and Zhang, Miao and Perrier, Nancy and Habra, Mouhammed Amir and Graham, Paul and Waguespack, Steven G},
  title = {TNM Staging and Overall Survival in Patients With Pheochromocytoma and Sympathetic Paraganglioma},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2023},
  volume = {108},
  number = {5},
  pages = {1132--1142},
  doi = {10.1210/clinem/dgac677}
}
Kostenlos starten →